Serum Insulin-like Factor 3, Testosterone and LH in Experimental and Therapeutic Testicular Suppression
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Serum Insulin-like Factor 3, Testosterone and LH in Experimental and Therapeutic Testicular Suppression. / Albrethsen, Jakob; Østergren, Peter Busch; Norup, Pernille Badsberg; Sønksen, Jens; Fode, Mikkel; Kistorp, Caroline; Nordsborg, Nikolai B.; Solheim, Sara Amalie; Mørkeberg, Jakob; Main, Katharina M.; Juul, Anders.
In: Journal of Clinical Endocrinology and Metabolism, Vol. 108, No. 11, 2023, p. 2834-2839.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Serum Insulin-like Factor 3, Testosterone and LH in Experimental and Therapeutic Testicular Suppression
AU - Albrethsen, Jakob
AU - Østergren, Peter Busch
AU - Norup, Pernille Badsberg
AU - Sønksen, Jens
AU - Fode, Mikkel
AU - Kistorp, Caroline
AU - Nordsborg, Nikolai B.
AU - Solheim, Sara Amalie
AU - Mørkeberg, Jakob
AU - Main, Katharina M.
AU - Juul, Anders
N1 - © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2023
Y1 - 2023
N2 - Background: Serum insulin-like factor 3 (INSL3) is a Leydig cell biomarker, but little is known about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular suppression.Aim: To study the concomitant changes in serum concentrations of INSL3, testosterone and LH during experimental and therapeutic testicular suppression.Methods: We included serum samples from three different cohorts comprising subjects before and after testicular suppression; 1) 6 healthy young men who were treated with androgens (Sustanon®, Aspen Pharma, Dublin, Ireland), 2) 10 transgender girls (male sex assigned at birth) who were treated with three-monthly GnRH agonist injections (Leuprorelinacetat, Abacus Medicine, Copenhagen, Denmark) and 3) 55 patients with prostate cancer who were randomized to surgical castration (bilateral subcapsular orchiectomy) or treatment with GnRH agonist (Triptorelin, Ipsen Pharma, Kista, Sweden). Serum INSL3 and testosterone concentrations were quantified in stored serum samples using validated liquid chromatography-tandem mass spectrometry methodologies, and LH was measured by an ultrasensitive immunoassay.Results: The circulating concentrations of INSL3, testosterone and LH decreased during experimental testicular suppression in healthy young men by Sustanon injections and subsequently returned to baseline levels after release of suppression. All 3 hormones decreased during therapeutic hormonal hypothalamus-pituitary-testicular suppression in transgender girls and in patients with prostate cancer.Conclusion: INSL3 resembles testosterone as a sensitive marker of testicular suppression and reflects Leydig cell function, also during exposure to exogenous testosterone. Serum INSL3 measurements may complement testosterone as a Leydig cell marker in male reproductive disorders, during therapeutic testicular suppression as well as in surveillance of illicit use of androgens.
AB - Background: Serum insulin-like factor 3 (INSL3) is a Leydig cell biomarker, but little is known about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular suppression.Aim: To study the concomitant changes in serum concentrations of INSL3, testosterone and LH during experimental and therapeutic testicular suppression.Methods: We included serum samples from three different cohorts comprising subjects before and after testicular suppression; 1) 6 healthy young men who were treated with androgens (Sustanon®, Aspen Pharma, Dublin, Ireland), 2) 10 transgender girls (male sex assigned at birth) who were treated with three-monthly GnRH agonist injections (Leuprorelinacetat, Abacus Medicine, Copenhagen, Denmark) and 3) 55 patients with prostate cancer who were randomized to surgical castration (bilateral subcapsular orchiectomy) or treatment with GnRH agonist (Triptorelin, Ipsen Pharma, Kista, Sweden). Serum INSL3 and testosterone concentrations were quantified in stored serum samples using validated liquid chromatography-tandem mass spectrometry methodologies, and LH was measured by an ultrasensitive immunoassay.Results: The circulating concentrations of INSL3, testosterone and LH decreased during experimental testicular suppression in healthy young men by Sustanon injections and subsequently returned to baseline levels after release of suppression. All 3 hormones decreased during therapeutic hormonal hypothalamus-pituitary-testicular suppression in transgender girls and in patients with prostate cancer.Conclusion: INSL3 resembles testosterone as a sensitive marker of testicular suppression and reflects Leydig cell function, also during exposure to exogenous testosterone. Serum INSL3 measurements may complement testosterone as a Leydig cell marker in male reproductive disorders, during therapeutic testicular suppression as well as in surveillance of illicit use of androgens.
KW - Faculty of Science
KW - INSL3
KW - LC-MS/MS
KW - Gonadal suppression
KW - Prostate cancer
KW - transgender girls (male sex assigned at birth)
U2 - 10.1210/clinem/dgad291
DO - 10.1210/clinem/dgad291
M3 - Journal article
C2 - 37235781
VL - 108
SP - 2834
EP - 2839
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 11
ER -
ID: 361583546